ASX Health Stocks: Here’s an update on Algorae’s AI-powered drugs discovery platform

Estimated read time 2 min read

Algorae gives updates on its AI-powered AlgoraeOS
AlgoraeOS can predict ombination drug targets using machine learning
AlgoraeOS also has access to the most powerful supercomputer in the Southern Hemisphere

 

Algorae Pharma (ASX:1AI) provided an update on Algorae Operating System (AlgoraeOS), the company’s proprietary artificial intelligence (AI) biopharmaceutical prediction platform.

AlgoraeOS is designed to predict combination drug targets using machine learning, deep learning, and neural network algorithms using the AlgoraeOS Database, which is a vast database of medical and scientific information curated for the purpose of AI drug discovery.

The platform is being developed by Algorae in collaboration with AI experts from the University of New South Wales (UNSW).

The company says that progress in developing this platform is ongoing.

Data acquisition  to underpin the AlgoraeOS Database is currently underway across four key pillars of information, which are: drug data, cellular data, chemistry, and biological data.

Initial data being inputted cover scientific and medical fields including chemical structure, clinical drug information, gene expression and drug perturbation data.

These data are obtained from some of the largest pharmaceutical companies in the world, originating most significantly from Merck and Co and Novartis AG.

 

Supercomputer Gadi

AlgoraeOS is anticipated to be operational in Q3 of this year, and will generate fixed dose combination drug targets that will expand Algorae’s therapeutic pipeline or may be licensed to third parties.

Fixed dose combination drugs are medicines that comprises two or more active pharmaceutical ingredients combined in a single dosage form.

Algorae has said that its goal is to uncover these synergistic fixed dose drug combinations in order to develop novel treatments for any medical condition.

Meanwhile, AlgoraeOS also has access to the most powerful supercomputer in the Southern Hemisphere, called ‘Gadi’, which is operated by the National Computational Infrastructure (NCI Australia).

Gadi has been used for the likes of climate modelling and natural disaster prediction. It contains more than 250,000 CPU cores, 930 Terabytes of memory and 640 Nvidia GPUs.

The supercomputer has peak operational capacity exceeding 10 petaflops, or 10 quadrillion floating-point operations per second.

 

Source: Supplied

Algorae share price today:

 



The post ASX Health Stocks: Here’s an update on Algorae’s AI-powered drugs discovery platform appeared first on Stockhead.

You May Also Like